Biliary Tract Cancer Clinical Trials in San Antonio, Texas

6 studies are recruiting for biliary tract cancer in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START - San Antonio, San Antonio, Texas

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

2. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT Health San Antonio - MD Anderson Cancer Center, San Antonio, Texas

   Locations

   14 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

3. Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

   The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Research Site, San Antonio, Texas

   Locations

   269 in total

   Run by

   AstraZeneca

   See if you can join NCT06467357 on ClinicalTrials.gov

4. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

   This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   6 in total

   Run by

   ModeX Therapeutics, An OPKO Health Company

   See if you can join NCT06239194 on ClinicalTrials.gov

5. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

   This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   3 in total

   Run by

   Zumutor Biologics Inc.

   See if you can join NCT06451497 on ClinicalTrials.gov

6. Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

   This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   11 in total

   Run by

   TiumBio Co., Ltd.

   See if you can join NCT05784688 on ClinicalTrials.gov